Effects of Botulinum Toxin Therapy on Health-Related Quality of Life Evaluated by the Oromandibular Dystonia Rating Scale
Oromandibular dystonia (OMD) refers to a focal dystonia in the stomatognathic system. Health-related quality of life (HRQoL) in isolated dystonia is associated with non-motor symptoms such as depression, anxiety, and pain, as well as motor symptoms. To evaluate HRQoL in patients with OMD, the therap...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6651/14/10/656 |
| _version_ | 1797469744219029504 |
|---|---|
| author | Kazuya Yoshida |
| author_facet | Kazuya Yoshida |
| author_sort | Kazuya Yoshida |
| collection | DOAJ |
| description | Oromandibular dystonia (OMD) refers to a focal dystonia in the stomatognathic system. Health-related quality of life (HRQoL) in isolated dystonia is associated with non-motor symptoms such as depression, anxiety, and pain, as well as motor symptoms. To evaluate HRQoL in patients with OMD, the therapeutic effects of botulinum neurotoxin (BoNT) therapy were assessed using a recently developed and validated comprehensive measurement tool called the Oromandibular Dystonia Rating Scale (OMDRS). Altogether, 408 patients (jaw closing dystonia, <i>n</i> = 223; tongue (lingual) dystonia, <i>n</i> = 86; jaw opening dystonia, <i>n</i> = 50; jaw deviation dystonia, <i>n</i> = 23; jaw protrusion dystonia, <i>n</i> = 13; and lip (labial) dystonia, <i>n</i> = 13) were evaluated at baseline and after the end of BoNT therapy or in a stable status. The total OMDRS score reduced significantly from 149.1 to 57.6 (<i>p</i> < 0.001). Mean improvement was 63.1%. All examiner-rated subscales (severity, disability, and pain) and patient-rated questionnaire scores (general, eating, speech, cosmetic, social/family life, sleep, annoyance, mood, and psychosocial function) were significantly lower at the endpoint than at baseline (<i>p</i> < 0.001). The BoNT injection had a highly positive impact on patient HRQoL, and the OMDRS could evaluate both motor phenomena and non-motor symptoms. |
| first_indexed | 2024-03-09T19:25:29Z |
| format | Article |
| id | doaj.art-031649da2c174e12a2fa9c8d03ca1709 |
| institution | Directory Open Access Journal |
| issn | 2072-6651 |
| language | English |
| last_indexed | 2024-03-09T19:25:29Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxins |
| spelling | doaj.art-031649da2c174e12a2fa9c8d03ca17092023-11-24T02:58:31ZengMDPI AGToxins2072-66512022-09-01141065610.3390/toxins14100656Effects of Botulinum Toxin Therapy on Health-Related Quality of Life Evaluated by the Oromandibular Dystonia Rating ScaleKazuya Yoshida0Department of Oral and Maxillofacial Surgery, National Hospital Organization, Kyoto Medical Center 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, JapanOromandibular dystonia (OMD) refers to a focal dystonia in the stomatognathic system. Health-related quality of life (HRQoL) in isolated dystonia is associated with non-motor symptoms such as depression, anxiety, and pain, as well as motor symptoms. To evaluate HRQoL in patients with OMD, the therapeutic effects of botulinum neurotoxin (BoNT) therapy were assessed using a recently developed and validated comprehensive measurement tool called the Oromandibular Dystonia Rating Scale (OMDRS). Altogether, 408 patients (jaw closing dystonia, <i>n</i> = 223; tongue (lingual) dystonia, <i>n</i> = 86; jaw opening dystonia, <i>n</i> = 50; jaw deviation dystonia, <i>n</i> = 23; jaw protrusion dystonia, <i>n</i> = 13; and lip (labial) dystonia, <i>n</i> = 13) were evaluated at baseline and after the end of BoNT therapy or in a stable status. The total OMDRS score reduced significantly from 149.1 to 57.6 (<i>p</i> < 0.001). Mean improvement was 63.1%. All examiner-rated subscales (severity, disability, and pain) and patient-rated questionnaire scores (general, eating, speech, cosmetic, social/family life, sleep, annoyance, mood, and psychosocial function) were significantly lower at the endpoint than at baseline (<i>p</i> < 0.001). The BoNT injection had a highly positive impact on patient HRQoL, and the OMDRS could evaluate both motor phenomena and non-motor symptoms.https://www.mdpi.com/2072-6651/14/10/656botulinum toxin therapyoromandibular dystoniabotulinum neurotoxinOromandibular Dystonia Rating Scale (OMDRS)health-related quality of lifenon-motor symptom |
| spellingShingle | Kazuya Yoshida Effects of Botulinum Toxin Therapy on Health-Related Quality of Life Evaluated by the Oromandibular Dystonia Rating Scale Toxins botulinum toxin therapy oromandibular dystonia botulinum neurotoxin Oromandibular Dystonia Rating Scale (OMDRS) health-related quality of life non-motor symptom |
| title | Effects of Botulinum Toxin Therapy on Health-Related Quality of Life Evaluated by the Oromandibular Dystonia Rating Scale |
| title_full | Effects of Botulinum Toxin Therapy on Health-Related Quality of Life Evaluated by the Oromandibular Dystonia Rating Scale |
| title_fullStr | Effects of Botulinum Toxin Therapy on Health-Related Quality of Life Evaluated by the Oromandibular Dystonia Rating Scale |
| title_full_unstemmed | Effects of Botulinum Toxin Therapy on Health-Related Quality of Life Evaluated by the Oromandibular Dystonia Rating Scale |
| title_short | Effects of Botulinum Toxin Therapy on Health-Related Quality of Life Evaluated by the Oromandibular Dystonia Rating Scale |
| title_sort | effects of botulinum toxin therapy on health related quality of life evaluated by the oromandibular dystonia rating scale |
| topic | botulinum toxin therapy oromandibular dystonia botulinum neurotoxin Oromandibular Dystonia Rating Scale (OMDRS) health-related quality of life non-motor symptom |
| url | https://www.mdpi.com/2072-6651/14/10/656 |
| work_keys_str_mv | AT kazuyayoshida effectsofbotulinumtoxintherapyonhealthrelatedqualityoflifeevaluatedbytheoromandibulardystoniaratingscale |